Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:SOPH NASDAQ:TRVI NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$9.98+6.4%$7.93$2.08▼$9.99$836.39M-0.441.14 million shs2.50 million shsSOPHSOPHiA GENETICS$3.35-3.2%$3.36$2.58▼$4.92$233.82M1.0194,542 shs46,472 shsTRVITrevi Therapeutics$7.27+0.1%$6.98$2.36▼$8.78$883.49M0.711.84 million shs2.07 million shsURGNUrogen Pharma$19.53+0.4%$17.21$3.42▼$21.01$899.84M1.11.02 million shs1.13 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+10.35%+21.50%+83.20%+322.52%SOPHSOPHiA GENETICS0.00%+0.29%+9.49%+14.19%-9.90%TRVITrevi Therapeutics0.00%-0.27%-0.95%+22.02%+129.75%URGNUrogen Pharma0.00%+5.14%+0.26%+289.00%+39.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals2.6785 of 5 stars3.51.00.00.03.32.50.6SOPHSOPHiA GENETICS1.9853 of 5 stars3.53.00.00.01.60.00.6TRVITrevi Therapeutics2.5643 of 5 stars3.62.00.00.02.92.50.0URGNUrogen Pharma4.5928 of 5 stars4.53.00.04.52.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.00Buy$12.2522.75% UpsideSOPHSOPHiA GENETICS 3.00Buy$8.00138.81% UpsideTRVITrevi Therapeutics 3.20Buy$20.11176.63% UpsideURGNUrogen Pharma 3.00Buy$32.0063.85% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, URGN, TRVI, and AMLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.008/21/2025TRVITrevi TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$18.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.008/8/2025TRVITrevi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $27.008/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $22.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/10/2025AMLXAmylyx PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$10.007/8/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.007/7/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/1/2025TRVITrevi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M10.19N/AN/A$1.88 per share5.31SOPHSOPHiA GENETICS$65.17M3.47N/AN/A$1.13 per share2.96TRVITrevi TherapeuticsN/AN/AN/AN/A$1.63 per shareN/AURGNUrogen Pharma$90.40M9.99N/AN/A($2.02) per share-9.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)Latest SOPH, URGN, TRVI, and AMLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/A8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25$0.33+$0.58$0.33$17.49 million$18.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A8.728.72SOPHSOPHiA GENETICS0.623.393.21TRVITrevi TherapeuticsN/A22.4222.42URGNUrogen PharmaN/A4.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%SOPHSOPHiA GENETICS31.59%TRVITrevi Therapeutics95.76%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%SOPHSOPHiA GENETICS4.88%TRVITrevi Therapeutics18.30%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableSOPHSOPHiA GENETICS52067.58 million64.28 millionNot OptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableSOPH, URGN, TRVI, and AMLX HeadlinesRecent News About These CompaniesPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21, 2025 | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comUroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call PresentationAugust 9, 2025 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak EarningsAugust 8, 2025 | marketbeat.comUroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...August 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOPH, URGN, TRVI, and AMLX Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$9.98 +0.60 (+6.40%) Closing price 04:00 PM EasternExtended Trading$9.77 -0.21 (-2.10%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.SOPHiA GENETICS NASDAQ:SOPH$3.35 -0.11 (-3.18%) Closing price 04:00 PM EasternExtended Trading$3.38 +0.03 (+0.90%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Trevi Therapeutics NASDAQ:TRVI$7.27 +0.01 (+0.14%) Closing price 04:00 PM EasternExtended Trading$7.18 -0.09 (-1.31%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Urogen Pharma NASDAQ:URGN$19.53 +0.08 (+0.41%) Closing price 04:00 PM EasternExtended Trading$19.44 -0.09 (-0.44%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
